Review
Oncology
Theresa Steeb, Anja Wessely, Anne Petzold, Christoph Kohl, Michael Erdmann, Carola Berking, Markus V. Heppt
Summary: The study summarized the efficacy and safety of c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma. Results showed that c-Kit inhibitors are a valuable treatment option for patients with KIT mutant melanoma, with nilotinib having the highest objective response rate.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Veterinary Sciences
Hiroyuki Tani, Ryo Miyamoto, Syunya Noguchi, Sena Kurita, Tomokazu Nagashima, Masaki Michishita, Naoko Yayoshi, Kyoichi Tamura, Makoto Bonkobara
Summary: This is a case report of a dog with malignant melanoma that showed a transient response to toceranib therapy, with molecular analysis indicating a KIT mutation associated with the response to toceranib in the tumor of this case.
BMC VETERINARY RESEARCH
(2021)
Article
Veterinary Sciences
David Conrad, Alexandra Kehl, Christoph Beitzinger, Thomas Metzler, Katja Steiger, Nicole Pfarr, Konrad Fischer, Robert Klopfleisch, Heike Aupperle-Lellbach
Summary: This study aimed to detect mutant genes in digital melanoma and found that canine digital melanoma differs from canine oral melanoma and human melanoma, especially in the proportion of RAS mutations.
VETERINARY SCIENCES
(2022)
Article
Oncology
Elizabeth I. Buchbinder, Jason L. Weirather, Michael Manos, Brian J. Quattrochi, Lynette M. Sholl, Ryan C. Brennick, Peter Bowling, Nancy Bailey, Lisa Magarace, Patrick A. Ott, Rizwan Haq, Benjamin Izar, Anita Giobbie-Hurder, F. Stephen Hodi
Summary: Mucosal melanoma, a rare form of melanoma, can be effectively treated with immune checkpoint blockade (ICB) despite lower response rates compared to cutaneous melanomas. A study found no significant correlation between mutational burden and response to ICB in mucosal melanoma patients, indicating the need for further exploration in this patient population. Genetic differences were observed in mucosal melanoma compared to cutaneous melanoma, highlighting the importance of additional research in this area.
Article
Oncology
Chiara Corti, Fabio Conforti, Laura Pala, Chiara Catania, Emilia Cocorocchio, Pier Francesco Ferrucci, Giuseppe Curigliano, Paola Queirolo, Tommaso de Pas
Summary: This study investigated the potential activity of avapritinib in mucosal melanoma and thymic carcinoma, two diseases with limited second-line treatment options. The results showed differential activity of avapritinib on KIT exon 17 mutations and potential implications for precision oncology.
EUROPEAN JOURNAL OF CANCER
(2022)
Article
Dermatology
David Millan-Esteban, Zaida Garcia-Casado, Esperanza Manrique-Silva, Amaya Viros, Rajiv Kumar, Simon Furney, Jose Antonio Lopez-Guerrero, Celia Requena, Jose Banuls, Victor Traves, Eduardo Nagore
Summary: KIT mutations are more frequent in acral and mucosal melanomas compared to non-acral cutaneous melanomas. These mutations are associated with aggressive melanomas characterized by ulceration, vascular invasiveness, and increased Breslow thickness, but not necessarily related to the development of nevi or chronic sun damage.
EUROPEAN JOURNAL OF DERMATOLOGY
(2021)
Article
Oncology
Suzanne George, Margaret von Mehren, Jonathan A. Fletcher, Jichao Sun, Sen Zhang, Justin R. Pritchard, John Graeme Hodgson, David Kerstein, Victor M. Rivera, Frank G. Haluska, Michael C. Heinrich
Summary: The study evaluated the efficacy of ponatinib for advanced gastrointestinal stromal tumors (GIST) and found that ponatinib demonstrated activity, particularly in KIT ex11-positive disease. There was a strong concordance of primary KIT mutations between plasma and tumor. Resistance was associated with the emergence of secondary mutations. Ponatinib was ineffective in patients with KIT exon 9 primary mutations. The safety profile was consistent with previous studies.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Min Ren, Jing Zhang, Yunyi Kong, Qianming Bai, Peng Qi, Ling Zhang, Qian Wang, Xiaoyan Zhou, Yong Chen, Xiaoli Zhu
Summary: Genetic alterations in Chinese melanoma patients show differences compared to Caucasian cohorts, with lower frequencies of BRAF and NRAS mutations. However, mutations in BRAF, C-KIT, and NRAS are consistent with clinicopathological features, and there is high concordance of gene mutations between primary and metastatic lesions.
ANNALS OF TRANSLATIONAL MEDICINE
(2022)
Review
Genetics & Heredity
Olivia Beaudoux, Jean-Baptiste Oudart, Laurence Riffaud, Laetitia Visseaux, Aude Marchal, Anne-Sophie Lebre, Florent Grange
Summary: This article systematically reviews molecular studies of primary mucosal melanomas (PMMs) to elucidate their pathogenesis and potential therapeutic targets. The study identified significantly mutated genes, including BRAF, NRAS, and KIT, as well as others that may be associated with future targeted therapies.
MOLECULAR DIAGNOSIS & THERAPY
(2022)
Article
Oncology
Shujing Li, Sien Zhao, Nianhai Liang, Shaoting Zhang, Liangying Zhang, Liangji Zhou, Anbu Liu, Xu Cao, Jinhai Tian, Yuanyuan Yu, Zhaoyang Fan, Kun Xiao, Ming Wang, Hui Zhao, Ru Bai, Jianmin Sun
Summary: In this study, the researchers investigated the role of SPRY4 in GISTs and its related mechanisms. They found that SPRY4 inhibits the expression and activation of KIT in GISTs, leading to decreased cell survival and proliferation. Additionally, SPRY4 enhances the inhibitory effect of Imatinib on primary KIT mutants, but has no effect on drug-resistant secondary KIT mutants.
Article
Oncology
Michael Jeffers, Christian Kappeler, Iris Kuss, Georg Beckmann, Daniel H. Mehnert, Johannes Fredebohm, Michael Teufel
Summary: In this retrospective and exploratory analysis of the GRID trial, it was found that regorafenib improved progression-free survival (PFS) regardless of KIT mutations in exons 9 and 11. Furthermore, the study did not identify a specific mutation pattern associated with regorafenib treatment. These findings support the results of the GRID trial and suggest that regorafenib can benefit patients with KIT mutations.
Article
Chemistry, Analytical
Ozlem Yaren, Jacquelyn McCarter, Andrew R. R. Morris, Kevin M. M. Bradley, Nilesh B. B. Karalkar, Daniel C. C. McLendon, Dongmin Kim, Bradley H. H. Eastmond, Nathan D. D. Burkett-Cadena, Barry W. W. Alto, Steven A. A. Benner
Summary: The recently reported DP-LAMP architecture has been proven to amplify viral RNA from SARS-CoV-2 with minimal sample processing. This molecular strategy allows for spatial separation and independent sequencing of target nucleic acids, making it an attractive option for the detection of arboviral RNA carried by mosquitoes in the field, when integrated with trap and sampling innovations.
ANALYTICAL CHEMISTRY
(2023)
Article
Oncology
Seungyeon Jung, Emma Armstrong, Alexander Z. Wei, Fei Ye, Aaron Lee, Matteo S. Carlino, Ryan J. Sullivan, Richard D. Carvajal, Alexander N. Shoushtari, Douglas B. Johnson
Summary: This multicenter study highlights KIT alterations that are sensitive to imatinib and further supports the use of imatinib in subsets of KIT-altered melanoma.
BRITISH JOURNAL OF CANCER
(2022)
Article
Medicine, General & Internal
Bruno Almeida Costa, Victor Zibara, Vasundhara Singh, Omid Hamid, Sonal Gandhi, Andrea P. P. Moy, Allison S. S. Betof Warner
Summary: This case report presents a patient who was diagnosed with metastatic melanoma more than 20 years after undergoing excision/grafting procedures for a giant CMN as a child. The patient had poor response to various treatment options, highlighting the importance of lifetime monitoring and evaluating novel therapies for patients with large/giant CMN.
FRONTIERS IN MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Anbu Liu, Shaoting Zhang, Ming Wang, Liangying Zhang, Shidong Xu, Ahmad Nasimian, Shujing Li, Sien Zhao, Xu Cao, Jinhai Tian, Yuanyuan Yu, Zhaoyang Fan, Kun Xiao, Hui Zhao, Julhash U. Kazi, Lijun Ma, Jianmin Sun
Summary: This study demonstrates that DDR1/2 contribute to KIT activation and enhance resistance to imatinib in GISTs, providing a rationale for further exploration of DDR1/2 targeting in GIST treatment.
MOLECULAR CARCINOGENESIS
(2023)
Article
Oncology
Sun Young Rha, Hyo Jin Lee, Jiyeon Lee
SUPPORTIVE CARE IN CANCER
(2020)
Article
Oncology
Hee Yeon Lee, Ji Hyung Hong, Jae Ho Byun, Hee-Jun Kim, Sun Kyung Baek, Jin Young Kim, Ki Hyang Kim, Jina Yun, Jung A. Kim, Kwonoh Park, Hyo Jin Lee, Jung Lim Lee, Young-Woong Won, Il Hwan Kim, Woo Kyun Bae, Kyong Hwa Park, Der-Sheng Sun, Suee Lee, Min-Young Lee, Guk Jin Lee, Sook Hee Hong, Yun Hwa Jung, Ho Jung An
CANCER RESEARCH AND TREATMENT
(2020)
Article
Oncology
Su Jin Lee, Jung Yong Hong, Kyung Kim, Kyoung-Mee Kim, So Young Kang, Taeyang Lee, Seung Tae Kim, Se Hoon Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang, Jeeyun Lee, Joon Oh Park
JOURNAL OF ONCOLOGY
(2020)
Article
Biochemistry & Molecular Biology
Hyera Kim, Su Jin Lee, In Kyoung Lee, Suejean C. Min, Hyun Hwan Sung, Byong Chang Jeong, Jeeyun Lee, Se Hoon Park
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2020)
Article
Medicine, General & Internal
Myung-Won Lee, Hyewon Ryu, Ik-Chan Song, Hwan-Jung Yun, Deog-Yeon Jo, Young Bok Ko, Hyo-Jin Lee
Article
Biochemistry & Molecular Biology
Sang-Hyun Lee, Jin-Man Kim, Dong Gwang Lee, Jangwook Lee, Jong-Gil Park, Tae-Su Han, Hyun-Soo Cho, Young-Lai Cho, Kwang-Hee Bae, Young-Jun Park, Seon-Jin Lee, Moo-Seung Lee, Yong-Min Huh, Deog Yeon Jo, Hwan-Jung Yun, Heung Jin Jeon, Nayoung Kim, Mina Joo, Jang-Seong Kim, Hyo Jin Lee, Jeong-Ki Min
Summary: The reduction of Dsg2 in gallbladder carcinoma is associated with poor prognosis, treatment resistance, and disease progression. Inhibiting Src activity could enhance therapeutic response to anti-EGFR therapy and improve clinical efficacy.
CELL DEATH AND DIFFERENTIATION
(2021)
Article
Medicine, General & Internal
Myung-Won Lee, Sang Hoon Yeon, Won-Hyoung Seo, Hyewon Ryu, Hyo-Jin Lee, Hwan-Jung Yun, Deog-Yeon Jo, Ik-Chan Song
Review
Andrology
In-Ho Kim, Hyo Jin Lee
TRANSLATIONAL ANDROLOGY AND UROLOGY
(2020)
Review
Biochemistry & Molecular Biology
In-Ho Kim, Hyo-Jin Lee
Summary: Immune checkpoint inhibitors have become the standard treatment for muscle-invasive bladder cancer, and perioperative immunotherapy shows promising efficacy. Future research will continue to explore predictive molecular biomarkers to enhance the effectiveness of systemic treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Review
Biochemistry & Molecular Biology
Hyunho Kim, Byoung Yong Shim, Seung-Ju Lee, Ji Youl Lee, Hyo-Jin Lee, In-Ho Kim
Summary: Renal cell carcinoma is a malignant tumor originating from the kidney tubular epithelium, with inactivation of the VHL gene commonly found in ccRCC. The VHL-HIF-VEGF/VEGFR pathway is a well-studied therapeutic target for metastatic ccRCC, with anti-angiogenic agents targeting VEGFR serving as the standard treatment over the past decade.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Nayoung Kim, Solbi Kim, Myung-Won Lee, Heung-Jin Jeon, Hyewon Ryu, Jin-Man Kim, Hyo-Jin Lee
Summary: MITF has been reported to play a role in the progression of melanoma and other cancer types, but its biological role in clear cell renal cell carcinoma (ccRCC) was largely unknown. This study revealed that MITF contributes to cell proliferation, migration, invasion, and tumor growth in ccRCC through activation of the RhoA/YAP signaling pathways. These findings suggest that MITF could be a potential therapeutic target for ccRCC treatment.
Article
Biochemistry & Molecular Biology
In-Ho Kim, Hyo Jin Lee
Summary: Approximately 400,000 patients are diagnosed with kidney cancer annually worldwide, resulting in approximately 170,000 deaths. Clear cell RCC is the most common subtype, accounting for about 85% of metastatic RCC cases. Immunotherapy with checkpoint inhibitors has shown promising results and become the standard of care for advanced clear cell RCC.
Article
Oncology
Kyungmin Lee, Sang-Hyun Lee, Wooil Kim, Jangwook Lee, Jong-Gil Park, Jang-Seong Kim, Jung Tae Kim, Yea Eun Kang, Minho Shong, Hyo Jin Lee, Jin-Man Kim, Won Gu Kim, Bon Seok Koo, Koon Soon Kim, Jeong-Ki Min
ENDOCRINE-RELATED CANCER
(2020)
Article
Hematology
Myung-Won Lee, Hyewon Ryu, Yoon-Seok Choi, Ik-Chan Song, Hyo-Jin Lee, Hwan-Jung Yun, Byung Joo Sun, Jin-Ok Jeong, Deog-Yeon Jo
Article
Oncology
Sup Kim, Jin Man Kim, Hyo Jin Lee, Jae Sung Lim, In-Ock Seong, Kyung-Hee Kim